scPharmaceuticals Inc. (SCPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
SCPH Stock Price Chart Interactive Chart >
SCPH Price/Volume Stats
|Current price||$5.41||52-week high||$9.64|
|Prev. close||$5.39||52-week low||$5.06|
|Day high||$5.56||Avg. volume||84,495|
|50-day MA||$6.05||Dividend yield||N/A|
|200-day MA||$7.04||Market Cap||147.99M|
scPharmaceuticals Inc. (SCPH) Company Bio
scPharmaceuticals Inc. engages in the development and commercialization of transformative pharmaceutical products. The company’s under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.
SCPH Latest News Stream
|Loading, please wait...|
SCPH Latest Social Stream
View Full SCPH Social Stream
Latest SCPH News From Around the Web
Below are the latest news stories about scPharmaceuticals Inc that investors may wish to consider to help them evaluate SCPH as an investment opportunity.
FREEDOM clinical study on track for topline results in Q3 2021 Ended Q1 with cash, cash equivalents, restricted cash and investments of $96.5 million BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. Business Update Conducted a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the FUROSCIX® New Drug Application (NDA) and requirements related to its resubmission.The Company is still in discussion with the FDA regarding the...
BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, will participate in two upcoming investor conferences. Event: Cowen 41st Annual Healthcare ConferenceThursday, March 410:30am EDT H.C. Wainwright Global Life Sciences ConferenceTuesday, March 9 – Wednesday, March 10 A webcast of Mr. Tucker’s presentation will be available on-demand as of 7am ET, Tuesday, March 9 A live webcast of both presentations can be accessed under “News & Events” in the Investor Relations section of the Compan...
Every investor in scPharmaceuticals Inc. ( NASDAQ:SCPH ) should be aware of the most powerful shareholder groups. Large...
ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional clinical studies to demonstrate the safety and efficacy of Furoscix. In December last year, the company received a Complete Response Letter due to the FDA's inability to conduct pre-approval inspections at two of scPharma's third-party manufacturing facilities due to travel restrictions. The letter also cited concerns regarding testing, labeling, and features of the combination product unrelated to the drug constituent, as well as deficiencies at the third-party facility where the company's off-the-shelf alcohol swabs are manufactured. The company still anticipates the need for inspections o...
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors
BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of William T. Abraham, M.D., to the company’s Board of Directors. Dr. Abraham currently serves as Professor of Internal Medicine (Cardiology), Physiology and Cell Biology and College of Medicine Distinguished Professor at The Ohio State University as well as Chief Medical Officer at V-Wave Ltd., a privately held developer of percutaneous implantable therapeutic devices for chronic heart failure patients. “I could not be more excited to welcome Dr. Abraham to our Board. H...
SCPH Price Returns